Actively Recruiting
Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients
Led by Peking University First Hospital · Updated on 2025-11-25
100
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients in the intensive care unit (ICU) often develop anxiety and agitation, sleep disturbances, and delirium. Delirium occurrence is associated with worse early and long-term outcomes. Dexmedetomidine and ketamine are recommended for sedation and analgesia in postoperative ICU patients, but each may induce side effects. The sedative effects of dexmedetomidine can help mitigate the neuropsychiatric side effects of esketamine. Recent studies showed that dexmedetomidine-esketamine combination improved analgesia and sleep quality without increasing side effects. This trial is designed to test the hypothesis that dexmedetomidine-esketamine combination for sedation and analgesia in postoperative ICU patients may reduce delirium.
CONDITIONS
Official Title
Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 60 years or older
- Admitted to the intensive care unit (ICU) after surgery
- Expected to stay in the ICU for at least one night
You will not qualify if you...
- History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis
- Presence of preoperative delirium, or inability to communicate due to coma, severe dementia, or language barrier
- Previously diagnosed obstructive sleep apnea, high risk of moderate-to-severe obstructive sleep apnea by STOP-Bang questionnaire, or body mass index over 30 kg/m��
- Preoperative left ventricular ejection fraction less than 30%, sick sinus syndrome, severe sinus bradycardia (heart rate less than 50 bpm), second-degree or higher atrioventricular block without pacemaker, or systolic blood pressure less than 90 mmHg despite vasopressors
- Comorbid hyperthyroidism or pheochromocytoma
- Severe liver dysfunction (Child-Pugh Class C), severe renal dysfunction requiring dialysis, or expected survival 24 hours or less
- After traumatic brain injury or neurosurgery
- Allergy to dexmedetomidine and/or esketamine
- Other conditions considered unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
D
Dong-Xin Wang, MD, PhD
CONTACT
L
Li Mo, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here